Solara Active Pharma Sciences reported a Q2 FY27 consolidated net profit of ₹28.59 crore, a sharp turnaround from a loss last year, with revenue up 33.1%.
₹28.59 crore
Q2 FY27 Net Profit
Q2 FY26: ₹9.29 crore loss→₹28.59 crore
📊 One chart explains it
Solara Active Pharma Sciences Consolidated Net Profit (₹ Crore)
Takeaway: Solara Active Pharma Sciences successfully turned its Q2 performance from a loss in FY26 to a strong profit in Q2 FY27.
⏳ Time Machine
How today’s news fits into the bigger picture
2017
Company Formed via Demerger
Solara Active Pharma Sciences was established through the demerger of the API business from Strides Shasun Ltd, becoming a pure-play API manufacturer.
FY26 (March 2026)
Reports Net Loss
Solara Active Pharma Sciences reported a net loss of ₹7.41 crore for the full fiscal year 2026, reflecting the challenges faced, particularly in the ibuprofen segment.
Q2 FY26 (Sept 2025)
Records Net Loss of ₹9.29 Crore
The company reported a consolidated net loss of ₹9.29 crore in the second quarter of FY26, which serves as the base for the current quarter's significant turnaround.
March 2026
Stock Hits 52-Week Low
Solara Active Pharma's stock hit a 52-week low of ₹422 on March 30, 2026, indicating the low point before its recent recovery.
H1 FY27 (Sept 2026)
Net Debt Reduced by 19%
The company reduced its net debt by ₹1,141 million (19%) in the first half of FY27 to ₹5,000 million, improving its net debt to EBITDA ratio to 1.8x.
Today
Solara Active Pharma Sciences reported a Q2 FY27 consolidated net profit of ₹28.59 crore, reversing last year's loss.
What happens next?
Management expects at least 10% base business growth and a 52-55% gross margin for FY27, with a strategic review of the ibuprofen business expected by November 2026.
Solara Active Pharma Sciences has announced a strong financial turnaround for Q2 FY27, reporting a consolidated net profit of ₹28.59 crore. This marks a significant recovery from a loss of ₹9.29 crore in the same quarter last year. The pharmaceutical company's total consolidated income surged by 33.1% year-on-year to ₹417.88 crore. Over the first half of FY27, net profit zoomed over 103-fold to ₹44.70 crore. The robust performance, particularly in its 'base business' and the near breakeven of its ibuprofen segment, propelled its shares up by 16% on October 16, 2026.
💭 If you're wondering…
Solara's 'base business' refers to its core portfolio of high-value catalogue generics and complex polymer APIs, excluding the commodity ibuprofen segment. This segment is crucial as it drives the majority of its revenue and profitability, as the ibuprofen business has historically faced challenges.
Did this story help?
Official sources
Knowledge Chain — tap a concept